PRF Technologies (PRFX) Retained Earnings (2019 - 2025)
PRF Technologies (PRFX) posted quarterly Retained Earnings of $69.8 million for Q4 2025, up 19.83% year-on-year from $58.3 million in Q4 2024, and up 218.83% on a QoQ basis from -$58.8 million in Q2 2025.
PRF Technologies (PRFX) Retained Earnings (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Retained Earnings for 7 consecutive years, with $69.8 million the latest figure, recorded in Q4 2025.
- Quarterly Retained Earnings rose 19.83% year-over-year to $69.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $69.8 million (up 19.83% YoY) and the FY2025 annual result came in at $69.8 million, up 19.83% from the prior year.
- Retained Earnings advanced to $69.8 million in Q4 2025 per PRFX's latest filing, from -$58.8 million in the prior quarter.
- Over the last five years, Retained Earnings for PRFX reached as high as $69.8 million in Q4 2025 and fell as low as -$58.8 million in Q2 2025.
- A 5-year average of -$11.8 million and a median of -$25.4 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings plunged 103.32% — and 2024, when it surged 4135.66%.
- Year by year, Retained Earnings stood at $41.7 million in 2021, then rose by 4.15% to $43.4 million in 2022, then tumbled by 103.32% to -$1.4 million in 2023, then jumped by 4135.66% to $58.3 million in 2024, then grew by 19.83% to $69.8 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $69.8 million, -$58.8 million, and $58.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | 69.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 69.83 Mn |
| Jun 30, 2025 | -58.77 Mn |
| Dec 31, 2024 | 58.28 Mn |
| Jun 30, 2024 | -54.68 Mn |
| Mar 31, 2024 | -47.37 Mn |
| Dec 31, 2023 | -1.44 Mn |
| Sep 30, 2023 | -36.97 Mn |
| Jun 30, 2023 | -37.01 Mn |
| Mar 31, 2023 | -34.83 Mn |
| Dec 31, 2022 | 43.45 Mn |
| Sep 30, 2022 | -29.35 Mn |
| Jun 30, 2022 | -27.24 Mn |
| Mar 31, 2022 | -25.42 Mn |
| Dec 31, 2021 | 41.72 Mn |
| Sep 30, 2021 | -21.99 Mn |
| Jun 30, 2021 | -20.22 Mn |
| Mar 31, 2021 | -18.52 Mn |
| Dec 31, 2020 | 33.02 Mn |
| Jun 30, 2020 | -14.39 Mn |
| Dec 31, 2019 | -12.43 Mn |